HMO Blend Production via Strain Engineering and Fermentation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing human milk oligosaccharide (HMO) blends with specific ratios of LNFP-I and LNT are limited, as commercial fermentation process parameters are not well described, leading to challenges in fine-tuning HMO compositions and achieving blends with LNFP-I as the most abundant HMO.
Innovation Solution
The use of strain engineering strategies, including over-expression of the lacY gene and deletion of the GlpR regulator, combined with modulation of lactose levels in the fermentation broth, to produce HMO blends with LNFP-I and LNT as predominant HMOs, using genetically engineered cells expressing specific glycosyltransferases and the colanic acid gene cluster.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If commercial fermentation process parameters are used for HMO production, then production can proceed with standard protocols, but the ability to fine-tune HMO compositions and achieve specific blend ratios is limited
Solution Approach 1:
The patent applies parameter changes by systematically varying fermentation conditions including lactose concentration (5-50 g/L), inoculum size (0.1-10% v/v), temperature (20-40°C), pH (5.0-7.0), and aeration rates (0.5-5.0 v/v/min) to optimize the production of LNFP-I and LNT HMOs. These parameter adjustments enable precise control over HMO blend composition while maintaining feasible fermentation processes.
2Manufacturing precision
If individual HMOs are produced and purified separately, then each HMO can be obtained in high purity, but the overall manufacturing efficiency and yield are reduced
Solution Approach 1:
The patent merges the production of multiple HMOs (LNFP-I and LNT) into a single fermentation process using a genetically engineered microorganism that co-produces these oligosaccharides. The blended HMO mixture is then purified as a single product stream rather than separating and purifying each HMO individually, thereby maintaining high purity while significantly improving manufacturing efficiency and overall yield.
3Ease of operation
If standard fermentation conditions are used, then the process is simple and robust, but the ability to produce tailored HMO blends for specific markets and applications is limited
Solution Approach 1:
The patent implements dynamic control of fermentation parameters including staged lactose addition, variable temperature profiles (20-40°C ranges), adjustable pH control (5.0-7.0), and modulated aeration rates to dynamically optimize HMO blend composition. This dynamic approach allows the same robust fermentation platform to produce tailored blends for different market requirements while maintaining operational simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the production of specific HMO blends with LNFP-I and LNT as the predominant HMOs, enabling more sustainable manufacturing by producing blends as mixtures rather than purifying individual HMOs, resulting in higher overall yields and tailored compositions for specific markets and biological effects.
Implementation Method 1
genetically engineered cells expressing specific glycosyltransferases and the colanic acid gene cluster
Implementation Method 2
Fermentation based processes have traditionally been developed for individual HMOs
Data Source
AI summary
This invention relates to a method of producing mixtures of various human milk oligosaccharides (HMOs) with unique HMO blend profiles, consisting predominantly of LNFP-I and LNT and of other HMOs in less significant amounts. The less abundant HMOs might be 2′-FL, LNT-II or DFL. The strategies for achieving specific HMO blends include strain engineering and fermentation methods.